| Application: | Internal Medicine |
|---|---|
| Usage Mode: | For external use |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Shape: | Oral Liquid |
| Type: | Organic Chemicals |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Product name | Ceftazidime for Injection |
| Specificaton | 0.25g/0.5g/1.0g |
| Certification | GMP ISO9001 ISO14001 |
| Standard | BP/CP |
| fuction | Ceftazidime for injection can be used for septicemia caused by sensitive gram-negative bacilli, lower respiratory tract infection, abdominal biliary tract infection, complex urinary tract infection and severe skin and soft tissue infection, etc. It is especially suitable for immunodeficiency infection caused by multi-drug resistant Gram-negative bacilli, nosocomial infection and central nervous system infection caused by gram-negative bacilli or Pseudomonas aeruginosa. |
| taboo | It is contraindicated for allergic reaction to this product or cephalosporin antibiotics. It should be avoided in patients with a history of penicillin anaphylactic shock. |
| Announcements | 1. Prior to the use of this product, the patient must be asked in detail if he/she has a prior history of allergy to this product, other cephalosporins, penicillins or other drugs. This product is used with caution in patients with penicillin-type allergy, as cross-allergy may occur. In case of anaphylactic shock, emergency measures such as epinephrine, keeping airway open, oxygen intake, glucocorticoid and antihistamine should be taken. 2. Patients with a history of gastrointestinal diseases, especially ulcerative colitis, localized colitis or antibiotic-associated colitis, should be used with caution (cephalosporins rarely produce pseudomeminal colitis). 3. Increased drug concentration and extended half-life may occur when routine dose is administered to patients with renal insufficiency, so dosage should be reduced for patients with renal insufficiency. Elevated blood concentrations can lead to convulsions, encephalopathy, flapping - like tremors, neuromuscular excitation, and myoclonus. 4. For severe gram-positive cocci infection, this product is not the preferred variety. 5. Under different storage conditions, the color of the powder can be darkened without affecting its activity. 6. Interference with diagnosis: direct antiglobulin (Coombs) test may be positive in patients taking this product; This product can make the urine sugar test of copper sulfate false positive; Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, blood urea nitrogen and serum creatinine can all be elevated. 7. The intravenous injection (20mg/ml) diluted with normal saline, 5% glucose injection or sodium lactate should not be stored at room temperature for more than 24 hours. 8. Long-term use of this product may lead to the overpropagation of insensitive or drug-resistant bacteria, which requires close observation. Once double infection occurs in the treatment process, corresponding measures should be taken. 9. This product can induce the production of type I lactamase by Enterobacteria, Pseudomonas, and Serrata. During the treatment, the pathogenic bacteria may develop resistance, leading to the failure of treatment. 10. This product may result in a false positive urine sugar test for copper assay. The enzymatic glucose oxidation assay is recommended. 11. This product is a class B drug in pregnancy, which is only used by pregnant women when there are clear indications. 12. A small amount of this product is secreted by milk, so it is appropriate for lactating women to stop breastfeeding. 13. Discarded pharmaceutical packaging should not be discarded at will. |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}